Osiris Therapeutics, Inc. (Osiris), is a stem cell therapeutic company. The Company focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The Company operates in two business segments: Therapeutics and Biosurgery. The Company's Therapeutics business is focused on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Company's Biosurgery business, works to harness the ability of cells and novel constructs to promote the body's natural healing. In the Company's Biosurgery business, the Company manufactures , market and distributes Grafix and Ovation for tissue repair. In the Company's Therapeutics segment, its pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee.